Aditya Naik
Overview
Explore the profile of Aditya Naik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
8
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ahluwalia K, Du Z, Martinez-Camarillo J, Naik A, Thomas B, Pollalis D, et al.
Int J Mol Sci
. 2024 Apr;
25(7).
PMID: 38612560
Retinal degenerative diseases, including age-related macular degeneration and retinitis pigmentosa, significantly contribute to adult blindness. The Royal College of Surgeons (RCS) rat is a well-established disease model for studying these...
2.
Lu A, Ebright B, Naik A, Tan H, Cohen N, Bouteiller J, et al.
Int J Mol Sci
. 2024 Feb;
25(4).
PMID: 38396738
The emergence and mutation of pathogenic viruses have been occurring at an unprecedented rate in recent decades. The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus...
3.
Ahluwalia K, Martinez-Camarillo J, Thomas B, Naik A, Gonzalez-Calle A, Pollalis D, et al.
Cells
. 2023 Jul;
12(13).
PMID: 37443724
Retinal degenerative diseases, including age-related macular degeneration (AMD) and retinitis pigmentosa, lack effective therapies. Conventional monotherapeutic approaches fail to target the multiple affected pathways in retinal degeneration. However, the retinal...
4.
Verma M, Samant C, Kale R, Patra S, Mahajan N, Gholve M, et al.
Biochem Biophys Res Commun
. 2022 Nov;
637:267-275.
PMID: 36410276
Phosphoinositide 3-kinase (PI3K) pathway mediates key signaling events downstream to B-cell receptor (BCR) for survival of mature B-cells, and overexpression or overactivation of PI3Kδ is crucial for B-cell malignancies such...
5.
Shukla M, Patra S, Verma M, Sadasivam G, Jana N, Mahangare S, et al.
J Med Chem
. 2020 Dec;
63(23):14700-14723.
PMID: 33297683
PI3Kδ inhibitors have been approved for B-cell malignancies like CLL, small lymphocytic lymphoma, and so forth. However, currently available PI3Kδ inhibitors are nonoptimal, showing weakness against at least one of...